Ionis Pharmaceuticals specializes in the discovery and development of RNA-targeted drugs.
Ionis Pharmaceuticals is a pharmaceutical company. It specializes in RNA-targeted drug discovery and development. Ionis has developed antisense technology, an efficient, broadly applicable drug discovery platform that can treat diseases where no other therapeutic approaches have proven effective.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 8, 2021 | Post-IPO Debt | $550M | — | — | — | Detail |
| Aug 27, 2012 | Post-IPO Debt | $201.25M | — | — | — | Detail |
| May 24, 1991 | IPO | — | — | — | — | Detail |
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Nov 14, 2022
Metagenomi
|
Corporate Round | $80M | Artificial Intelligence | Yes |
|
Jan 5, 2021
Aro Biotherapeutics
|
Series A | $88M | Biotechnology | — |
|
Jan 9, 2020
Empirico
|
Series A | $17M | Biotechnology | Yes |
|
Mar 1, 2007
Atlantic Healthcare
|
Seed | $6.80M | Biotechnology | Yes |
Ionis Pharmaceuticals has acquired 1 organizations. Their most recent acquisition was Akcea Therapeutics on Aug 31, 2020. They acquired Akcea Therapeutics for $500M.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Aug 31, 2020
Akcea Therapeutics
|
Biotechnology | acquisition | $ 500M | Detail |